MOTS-C

What Is MOTS‑C?

MOTS‑C (Mitochondrial Open Reading Frame of the 12S rRNA‑C) is a bioactive peptide encoded by mitochondrial DNA, classified as a mitochondrial‑derived peptide (MDP). Unlike nuclear‑encoded peptides, MOTS‑C originates from mitochondrial genetic sequences, highlighting the organelle’s role as a signaling hub beyond energy production. It has been studied for its ability to regulate metabolism, stress adaptation, and cellular resilience.

Mechanism of Action

MOTS‑C influences metabolic pathways by activating AMP‑activated protein kinase (AMPK), a master regulator of cellular energy balance. Through AMPK signaling, MOTS‑C enhances glucose uptake, improves insulin sensitivity, and promotes fatty acid oxidation. It also modulates stress response pathways, supporting mitochondrial function and protecting against metabolic dysfunction. MOTS‑C’s activity extends to skeletal muscle, where it enhances exercise capacity and endurance by optimizing energy utilization.

Research & Clinical Data

Preclinical studies demonstrate MOTS‑C’s potential in combating obesity, insulin resistance, and age‑related metabolic decline. Animal models show improved glucose tolerance, enhanced exercise performance, and protection against diet‑induced metabolic disorders. Early human data suggest MOTS‑C levels decline with age, linking it to longevity research. Clinical trials remain limited, and regulatory approval has not been established. Its role as a mitochondrial‑derived peptide positions MOTS‑C at the intersection of metabolism, aging, and regenerative medicine.

Purity & Quality

Reference‑grade peptide material. Certificate of Analysis available per batch. Regulatory status: investigational, not FDA‑ or EMA‑approved.

Classification & Handling Class: Mitochondrial‑derived peptide | Source: mtDNA (12S rRNA region) | Administration: Subcutaneous injection (investigational) | Storage: 2–8°C refrigerated, protect from light | Regulatory: Not FDA/EMA approved